Itacitinib Monotherapy for Low Risk Graft-vs-Host Disease
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Itacitinib (Primary)
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- 25 Mar 2019 Status changed from not yet recruiting to recruiting.
- 25 Feb 2019 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health :NCT03846479)
- 17 Feb 2019 Status changed from planning to not yet recruiting.